Prophylaxis of Pseudophakic Cystoid Macular Edema with Intraoperative Pegaptanib

Gallego-Pinazo, Roberto; Arévalo, J. Fernando; Udaondo, Patricia; García-Delpech, S.; Dolz-Marco, Rosa; Díaz-Llopis, M.

doi:10.1089/jop.2011.0089

Cited by 6 publications

(3 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…33,98 Prophylaxis using anti-VEGF treatments has also been suggested; prophylactic treatment with pegaptanib (N ¼ 250) administered after cataract surgery together with dexamethasone-tobramycin administered 4 times daily led to a significantly lower incidence of CME (0.4%) compared with dexamethasone-tobramycin treatment alone (N ¼ 250; 4.4%) after uncomplicated cataract surgery (P ¼ 0.009). 31 Although there were no reported safety concerns in this study, there are added costs and risks associated with intravitreal injections. In addition, as preoperative use of PGAs has been identified as a risk factor, there is a need for guidance in clinical practice regarding possible withdrawal of PGA treatment in patients with mild glaucoma undergoing cataract surgery and the appropriate duration of this withdrawal to minimize the likelihood of postoperative development of CME.…”

Section: Prophylactic Treatments For Cmementioning

confidence: 74%

Cystoid macular edema related to cataract surgery and topical prostaglandin analogs: Mechanism, diagnosis, and management

Holló

Aung

Cantor

et al. 2020

Survey of Ophthalmology

View full text Add to dashboard Cite

show abstract

Section: Prophylactic Treatments For Cmementioning

confidence: 74%

Cystoid macular edema related to cataract surgery and topical prostaglandin analogs: Mechanism, diagnosis, and management

Holló

Aung

Cantor

et al. 2020

Survey of Ophthalmology

View full text Add to dashboard Cite

show abstract

“…Despite recent advances in cataract surgery technique and instrumentation, pseudophakic cystoid macular edema (CME) remains a relatively frequent complication of cataract surgery even after uncomplicated surgery [1,2]. Pseudophakic CME develops angiographically after uneventful cataract surgery in up to 20-30 % of patients after extracapsular cataract extraction/phacoemulsification [1,3,4].…”

Section: Introductionmentioning

confidence: 99%

Intravitreal infliximab for refractory pseudophakic cystoid macular edema: results of the Pan-American Collaborative Retina Study Group

Arévalo²,

Hernández-Bogantes

et al. 2012

Int Ophthalmol

View full text Add to dashboard Cite

Inflammation is the major etiologic factor in the development of pseudophakic cystoid macular edema (CME). Several soluble mediators of inflammation such as tumor necrosis factor alpha (TNF-α) have been implicated in the pathogenesis of ocular inflammation. The purpose of this study is to report the short-term visual and anatomic outcomes following intravitreal injections of infliximab in eyes with refractory CME secondary to cataract surgery. An interventional, retrospective study of 7 eyes with refractory CME that were injected with 1 mg of infliximab. The main outcome measures were best-corrected visual acuity (BCVA) and central macular thickness (CMT) at 6-month follow-up. At the 6 month follow-up, BCVA improved from 1.14 ± 0.59 logMAR at baseline to 0.51 ± 0.35 logMAR (p = 0.0156). CMT also improved from 584 ± 159 μm at baseline to 327 ± 127 μm at 6 months (p = 0.0111). No systemic adverse events were reported in these patients. There was a single episode of uveitis that responded to topical steroids. Inhibition of TNF-α may be beneficial in the treatment of refractory pseudophakic CME.

show abstract

“…pseudophakic macular edema is one of the frequent complications of cataract surgery which is a severe postoperative inflammatory response [ 1 , 2 ]. Inflammation is generally accepted as the main etiologic factor in the development of pseudophakic cystoid macular edema (CME).…”

Section: Introductionmentioning

confidence: 99%

The effects of intravitreal adalimumab injection on pseudophakic macular edema

et al. 2020

View full text Add to dashboard Cite

Objective Pseudophakic macular edema is a frequent complication following cataract surgery. Inflammation is a major etiologic factor in the development of pseudophakic cystoid macular edema. Tumor necrosis factor-alpha has an important role in ocular inflammation. Adalimumab (Humira) is an inhibitor of tumor necrosis factor-alpha that has been approved in the United States. An open-label, uncontrolled, prospective, interventional study of five consecutive patients (5 eyes) with cystoid macular edema who were treated with off-label intravitreal adalimumab at Khalili Hospital was conducted. Slit-lamp examination and optical coherence tomography were done for all patients. Results No statistically significant difference was detected between best corrected visual acuity and central macular thickness before and after injection in pseudophakic macular edema. One patient developed uveitis approximately 2 weeks after injection. Based on the results, adalimumab does not appear to be an effective treatment for pseudophakic macular edema, and it may cause uveitis. Caution should be exercised when using this drug. Trial registration Iranian Registry of Clinical Trials IRCT2016100430130N1, 2016.12.03, Retrospectively registered

show abstract

Prophylaxis of Pseudophakic Cystoid Macular Edema with Intraoperative Pegaptanib

Cited by 6 publications

References 22 publications

Cystoid macular edema related to cataract surgery and topical prostaglandin analogs: Mechanism, diagnosis, and management

Cystoid macular edema related to cataract surgery and topical prostaglandin analogs: Mechanism, diagnosis, and management

Intravitreal infliximab for refractory pseudophakic cystoid macular edema: results of the Pan-American Collaborative Retina Study Group

The effects of intravitreal adalimumab injection on pseudophakic macular edema

Contact Info

Product

Resources

About